SARS-CoV-2 Antibody Response to 2 or 3 Doses of BioNTech-Pfizer Vaccine in Patients With Cancer

JAMA Oncology

EMBARGOED FOR RELEASE: 11 A.M. (ET), FRIDAY, JANUARY 7, 2022

Media advisory: The full study is linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamaoncology/fullarticle/10.1001/jamaoncol.2021.7777?guestAccessKey=64f57de0-65f5-4ccc-9c30-3abe123b5e3b&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=010722

 

What The Study Did: This study assessed the antibody response to two or three doses of the BioNTech-Pfizer SARS-CoV-2 vaccine in 163 patients treated with anticancer agents for solid tumors.

Authors: Charlotte Fenioux, M.D., of Hôpital Henri Mondor in Créteil, France, is the corresponding author.

 

(doi:10.1001/jamaoncol.2021.7777)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.